Drugs / MUPADOLIMAB
MUPADOLIMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04464395 | Jul 2020 → Mar 2021 | COVID-19 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03454451 | Apr 2018 → Dec 2022 | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 | Corvus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04734873 | Feb → Aug 2021 | COVID-19 | Corvus Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results corvuspharma.com ↗
IND approved in China for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) |
| 2022-09-26 | Corvus Pharmaceuticals, Inc. | Regulatory Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China corvuspharma.com ↗ |
| 2021-11-12 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting corvuspharma.com ↗
The data presented at SITC showed that mupadolimab doses of 12mg/kg are optimal, resulting in complete occupancy of the CD73 target and maximal effects on B cell activation. |
| 2021-09-22 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease corvuspharma.com ↗ |
| 2020-11-11 | Corvus Pharmaceuticals, Inc. | Results Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual Meeting corvuspharma.com ↗
Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 |
| 2020-11-09 | Corvus Pharmaceuticals, Inc. | Results Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting corvuspharma.com ↗
Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2 |
| 2020-10-05 | Corvus Pharmaceuticals, Inc. | Results New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19 corvuspharma.com ↗
The 56-day follow-up results showed a dose-response, with higher and more prolonged titers of anti-SARS-CoV-2 antibodies in the 1.0 mg/kg cohort compared to the 0.3 mg/kg cohort. |
| 2020-09-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19 corvuspharma.com ↗
In addition, all of these patients were discharged from the hospital with clinical improvement and none experienced any drug-related safety issues. |
| 2019-11-08 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting corvuspharma.com ↗
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. |
| 2019-06-02 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting corvuspharma.com ↗
Initial Results demonstrated dose-dependent disease control in patients with advanced, refractory disease when administered as a monotherapy and in combination with ciforadenant (CPI-444) |
| 2019-02-06 | Corvus Pharmaceuticals, Inc. | Results Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs CPI-444 and CPI-006 at Immuno-Oncology 360° Conference corvuspharma.com ↗ |
| 2018-11-10 | Corvus Pharmaceuticals, Inc. | Results Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting corvuspharma.com ↗
Early clinical data from an ongoing Phase 1/1b study evaluating CPI-006 as a monotherapy showing evidence of immune activation of B cells were presented in a poster session. |
All press releases naming this drug 21 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUPADOLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802200 ↗ |
| Known as | CPI-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04734873 ↗ |
| Known as | CPX-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802200 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody” NCT04464395 ↗ |
| Route | Intravenous | “Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days” NCT03454451 ↗ |